Ocular Therapeutix, Inc (OCUL): R&D Expense
$197.10M
Year ended 2025-12-31
$223.51M
Trailing 12 months to 2026-06-30
+54.5%
3-year compound annual growth
+47.0%
5-year compound annual growth
+22.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $197.10M | +54.4% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $127.64M | +109.0% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $61.05M | +14.2% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $53.46M | +6.7% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $50.08M | +74.5% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $28.69M | -30.2% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $41.09M | +11.3% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $36.91M | +19.5% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $30.88M | +14.1% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $27.07M | +1.7% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $26.61M | +40.9% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $18.88M | +79.5% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $10.52M | -8.9% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $11.54M | n/a | 2015-03-20, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $197.10M | +54.4% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $339.54M | +12.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
Compare OCUL, QTTB, AGIO, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗